NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading SUPN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a speculative growth opportunity. The company is currently loss-making but operates in a sector with favorable momentum, which could support its recovery.
The market appears to have priced in a fragile valuation, reflecting a premium compared to peers. There is an expectations gap, indicating that investors may not fully believe in the company's ability to improve its financial performance.
Management is stable and focused on integrating recent acquisitions, but the company's recent financial performance has been neutral. There is a moderate risk of missing future earnings, which could impact investor sentiment.
The thesis hinges on the performance of sector bellwethers like HLN, TEVA, and ZTS. If these companies continue to perform well, it could provide a tailwind for SUPN. Conversely, any negative guidance from these peers could pose a risk.
Overall, SUPN's situation is mixed, with some positive management actions but significant risks ahead. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: A slowdown in revenue growth may show problems with key products.
Confirms:Q2 total revenue growth below 30% year over year would indicate a slowdown.
Disproves:Q2 revenue growth of 30% or more year over year would confirm strong momentum.
Why it matters: Reaffirming revenue guidance shows confidence in growth and execution. It can boost investor trust.
Confirms:Management confirms full year 2026 revenue guidance of $840 million to $870 million.
Disproves:Management cuts the revenue guidance to below $840 million.
Why it matters: Reiterating guidance shows confidence in revenue growth. This can help keep investors calm.
Confirms:Management confirms full year 2026 revenue guidance during the next earnings call.
Disproves:Management lowers or withdraws the full year 2026 revenue guidance.
Why it matters: The earnings results will reveal if revenue growth continues or slows. This is key for future guidance.
Confirms one read:Total revenue growth is over 39% compared to last year. This shows strong performance.
Confirms the other:Total revenue growth is under 39% compared to last year. This shows possible problems.
Why it matters: Earnings results will show how well Supernus is performing. This affects investor confidence.
Confirms one read:Earnings per share (EPS) is over $0.10. This shows better performance.
Confirms the other:EPS falls below $0.00, showing continued losses.
Why it matters: Good results could show SPN-817's potential and increase Supernus's pipeline value.
Confirms one read:Phase 2b trial shows strong results in reducing focal seizures.
Confirms the other:Phase 2b trial fails to meet primary endpoint.
Why it matters: News about milestones can change how much money Supernus needs. It can also affect future cash flow.
Confirms:They announced a milestone that helps cash flow.
Disproves:They announced a missed milestone. This increases financial strain.
Why it matters: Meeting this target would show higher profits. It would also show better efficiency in operations.
Confirms:Adjusted operating earnings reach $140 million or more for the full year.
Disproves:Adjusted operating earnings fall below $140 million for the full year.
Why it matters: Missing earnings guidance may show problems in operations. This can hurt trust from investors.
Confirms:Earnings below $140 million for 2026 would show problems in operations.
Disproves:Earnings of $140 million or more would show good performance.
Why it matters: Approval would help keep supply steady and boost sales for ONAPGO.
Confirms:FDA will announce approval for the second ONAPGO supplier before mid-2027.
Disproves:Delay in FDA approval or failure to secure the second supplier.
Why it matters: Updates on earnings guidance show how well the company controls costs and revenue.
Confirms one read:Management raises earnings guidance in the next earnings call.
Confirms the other:Management lowers earnings guidance in the next earnings call.
Why it matters: Growth in collaboration revenue shows strong partnerships. It also shows demand for products.
Confirms:Collaboration revenue from ZURZUVAE goes up by 50% or more each year.
Disproves:Collaboration revenue from ZURZUVAE goes up by less than 50% each year.
Why it matters: Good results could help the product pipeline. This may increase investor confidence in Supernus.
Confirms:Management announces positive results from the Phase 2b trial of SPN-817.
Disproves:Trial results are bad or unclear. This raises worries about the product's success.
